Human ultrarare genetic disorders of sulfur metabolism demonstrate redundancies in H 2 S homeostasis.

Regulation of H ₂ S homeostasis in humans is poorly understood. Therefore, we assessed the importance of individual enzymes in synthesis and catabolism of H ₂ S by studying patients with respective genetic defects. We analyzed sulfur compounds (including bioavailable sulfide) in 37 untreated or insufficiently treated patients with seven ultrarare enzyme deficiencies and compared them to 63 controls. Surprisingly, we observed that patients with severe deficiency in cystathionine β-synthase (CBS) or cystathionine γ-lyase (CSE) - the enzymes primarily responsible for H ₂ S synthesis - exhibited increased and normal levels of bioavailable sulfide, respectively. However, an approximately 21-fold increase of urinary homolanthionine in CBS deficiency strongly suggests that lacking CBS activity is compensated for by an increase in CSE-dependent H ₂ S synthesis from accumulating homocysteine, which suggests a control of H ₂ S homeostasis in vivo. In deficiency of sulfide:quinone oxidoreductase - the first enzyme in mitochondrial H ₂ S oxidation - we found normal H ₂ S concentrations in a symptomatic patient and his asymptomatic sibling, and elevated levels in an asymptomatic sibling, challenging the requirement for this enzyme in catabolizing H ₂ S under physiological conditions. Patients with ethylmalonic encephalopathy and sulfite oxidase/molybdenum cofactor deficiencies exhibited massive accumulation of thiosulfate and sulfite with formation of large amounts of S-sulfocysteine and S-sulfohomocysteine, increased renal losses of sulfur compounds and concomitant strong reduction in plasma total cysteine. Our results demonstrate the value of a comprehensive assessment of sulfur compounds in severe disorders of homocysteine/cysteine metabolism and provide evidence for redundancy and compensatory mechanisms in the maintenance of H ₂ S homeostasis.
Competing Interests: Declaration of competing interest GS declares that he serves as CEO of Colbourne Pharmaceuticals consulting Origin Biosciences in the developments of treatments for MoCD type A, BS is investigator in clinical trials to develop a treatment for MoCD-A sponsored by Origin Biosciences Inc. The other authors do not declare any competing interests.
(Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)